Summary of Replimune Q4 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: As of March 31, 2025, Replimune reported cash and cash equivalents of $483.8 million, an increase from $420.7 million year-over-year.

Cash Runway: The company expects its cash position to fund operations into the fourth quarter of 2026.

Expenses:

R&D Expenses: $54 million for Q4 2025, totaling $189.4 million for the fiscal year, up from $175 million in FY 2024.

SG&A Expenses: $25.4 million for Q4 2025, totaling $72.2 million for the fiscal year, compared to $59.8 million in FY 2024.

Net Loss: Reported a net loss of $74.1 million for Q4 and $247.3 million for the fiscal year, compared to $55.1 million and $215.8 million in the previous year.

2Strategic Updates and Business Highlights

Product Development: Replimune is focused on the potential approval and launch of RP1 for advanced melanoma patients who have failed anti-PD-1 therapy, with a PDUFA date of July 22, 2025.

Regulatory Progress: RP1 has received breakthrough therapy designation and priority review status from the FDA.

Clinical Trials: The Ignite 3 trial is underway, focusing on overall survival as the primary endpoint, with over 100 sites planned globally.

Commercial Readiness: The company has built out its commercial infrastructure, including a trained team of approximately 60 people and established partnerships with specialty distributors for next-day delivery.

3Forward Guidance and Outlook

Launch Preparations: The company is optimistic about the launch of RP1, anticipating broad adoption among oncologists and interventional radiologists.

Market Opportunity: Approximately 13,000 patients in the U.S. progress on or after PD-1 treatment annually, with 80% eligible for RP1.

Future Development: Plans to discuss the development of RP2 and RPX at the upcoming Investor Day on June 24, 2025.

4Bad News, Challenges, or Points of Concern

Increased Losses: The significant increase in net loss year-over-year raises concerns about the sustainability of current spending levels.

Market Competition: The treatment landscape for melanoma is competitive, and there is uncertainty regarding the uptake of RP1 in a market with existing therapies.

Enrollment Challenges: While enrollment in the Ignite 3 trial is on track, the company acknowledges that it may take a couple of years to complete due to the study size and patient population.

5Notable Q&A Insights

Medical Education at ASCO: Replimune plans to showcase data on RP1's efficacy at the upcoming ASCO conference, emphasizing the rationale for deeper lesion injections.

Launch Trajectory: The company expects rapid adoption of RP1, especially in hospital settings, with a significant percentage of key accounts already trained for tumor injections.

Regulatory Interactions: The company reported positive interactions with the FDA, completing necessary inspections without impediments to the upcoming PDUFA date.

Broad Label Expectations: Replimune is confident that the label for RP1 will reflect a broad patient population based on the diverse enrollment in the Ignite trial. Overall, Replimune is positioned for a significant upcoming milestone with the potential approval of RP1, while also navigating challenges related to financial losses and competitive pressures in the oncology market.